Home>Topics>Authors>Damien Conover

Damien Conover

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
  1. J&J Faces Headwinds in 2015

    Headlines

    Tue, 20 Jan 2015

    The pharmaceutical giant turned in an in line fourth-quarter, but new competition and a strong dollar will slow growth in 2015, writes Morningstar’s Damien Conover .

  2. From Fear of an Overheating U.S. Economy to Doom and Gloom in One Easy Week

    Headlines

    Sat, 17 Jan 2015

    the long-term trend of higher and higher prices had been broken. According to Morningstar healthcare team leader Damien Conover , a combination of higher prices from the consolidated generics industry, fewer drugs going off patent, and more

  3. Our 2014 Big Pharma Pipeline Rankings: Who Came Out on Top?

    Video Reports

    Fri, 2 Jan 2015

    Coffina. I'm joined today by Damien Conover , who is the director of our health ..... Damien, thanks for joining me. Damien Conover : Matt, thanks for having me ..... Coffina: Thanks for joining me, Damien . Conover : Matt, thanks for having me

    Damien Conover found at 0:06, 3:45

    Coffina: For Morningstar StockInvestor , I'm Matt Coffina. I'm joined today by Damien Conover , who is the director of our health-care team. We are going to talk about pharmaceutical firms' pipelines. Damien, thanks for joining me. Damien Conover : Matt, thanks for having me. Coffina: Every year, you do this analysis using our proprietary box methodology, as we call it, basically
    strikeouts, and that really hurt their pipeline. Coffina: Thanks for joining me, Damien . Conover : Matt, thanks for having me. Coffina: In conclusion, in this year's Big Pharma ranking, Merck and [TICKER:SNY] Sanofi came out on top--Merck because
  4. Friday Five: China's Tricky Gambit for Growth

    Video Reports

    Thu, 11 Dec 2014

    acquiring Cubist. What's our take on the deal? Glaser: Merck is going to spend $9.5 billion for Cubist, and Damien Conover , our health-care analyst, thinks this is about expanding Merck's presence into the hospital acute-care segment

    Damien Conover found at 3:26

    deal? Glaser: Merck is going to spend $9.5 billion for Cubist, and Damien Conover , our health-care analyst, thinks this is about expanding Merck's presence into the hospital acute-care segment, and he thinks that's something that will
  5. A Shift in Health-Care M&A Activity

    Headlines

    Sat, 23 Aug 2014

    rest of 2014 might hold for M&A activity in health care, I recently talked with Morningstar health-care analysts Damien Conover , David Krempa, and Michael Waterhouse on May 31. Our discussion has been edited for clarity and length. Question

  6. Health Care a Leader in Moat Stocks

    Video Reports

    Tue, 22 Jul 2014

    great competitive advantages. I'm here today with Damien Conover , our director of health-care research, to look ..... health-care space. Damien, thanks for joining me. Damien Conover : Thanks for having me, Jeremy. Glaser: You wrote

    Damien Conover found at 0:11

    delves into finding companies with great competitive advantages. I'm here today with Damien Conover , our director of health-care research, to look at moats in the health-care space. Damien, thanks for joining me. Damien Conover : Thanks for having me, Jeremy. Glaser: You wrote in the book that health-care companies have a higher preponderance of moats than a
  7. The Friday Five

    Video Reports

    Fri, 18 Jul 2014

    the coming years from other companies, so that growth will moderate. But they have a pretty strong pipeline, and Damien Conover , our [TICKER:JNJ] Johnson & Johnson analyst, really sees that their patent losses are pretty manageable

    Damien Conover found at 5:05

    that growth will moderate. But they have a pretty strong pipeline, and Damien Conover , our [TICKER:JNJ] Johnson & Johnson analyst, really sees that their patent losses are pretty manageable. [Those patent losses] tend to be in products
  8. J&J's Strong 2Q Led by Pharmaceuticals

    Headlines

    Tue, 15 Jul 2014

    Unexpectedly robust sales of hepatitis C drug Olysio helped lift the drug giant’s pharma segment, while medical devices struggled, says Morningstar’s Damien Conover .

  9. The Friday Five

    Video Reports

    Thu, 8 May 2014

    includes things like Claritin, Coppertone, and Dr. Scholl's foot insoles--and sending them over to Bayer. Damien Conover , our health-care analyst, thinks this is a good deal for both sides. Merck is getting a good price for these

    Damien Conover found at 2:54

    Claritin, Coppertone, and Dr. Scholl's foot insoles--and sending them over to Bayer. Damien Conover , our health-care analyst, thinks this is a good deal for both sides. Merck is getting a good price for these businesses right
  10. The Friday Five

    Video Reports

    Thu, 1 May 2014

    AstraZeneca possibly having a deal. What's our take on this? Glaser: This deal likely makes a lot more sense. Damien Conover , our health-care analyst, sees [TICKER:AZN] AstraZeneca as having somewhat of the bloated cost structure

    Damien Conover found at 2:35

    take on this? Glaser: This deal likely makes a lot more sense. Damien Conover , our health-care analyst, sees [TICKER:AZN] AstraZeneca as having somewhat of the bloated cost structure. Pfizer would be able to come in and get
« Prev123Next »
Content Partners